Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.

Abstract

Twenty cats with spontaneously arising tumors received oral lomustine at a dose range of 32 to 59 mg/m2 every 21 days. Due to biohazard concerns associated with lomustine capsule reformulation, a standardized 10-mg capsule dosage was used for all cats regardless of body weight. Severe hematological toxicity was infrequent, with the incidence of either grade III or IV neutropenia and thrombocytopenia being 4.1% and 1.0%, respectively. Cats receiving higher cumulative doses of lomustine trended toward a greater likelihood for progressive neutropenia (P=0.07). Two cats with lymphoma, two cats with fibrosarcoma, and one cat with multiple myeloma achieved a measurable partial response to lomustine therapy. Cats treated with higher dosages of lomustine trended toward statistically significant higher response rates (P=0.07).

• Authors: Timothy M Fan, Barbara E Kitchell, Ravinder S Dhaliwal, Pamela D Jones, John G Hintermeister, Biman C Paria
• Journal: Journal of the American Animal Hospital Association (J Am Anim Hosp Assoc) 2002 Jul-Aug Vol. 38 Issue 4 Pg. 357-63 ISSN: 0587-2871 [Print] United States
• PMID: 12118689 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Lomustine

Topics

• Administration, Oral
• Animals
• Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, therapeutic use)
• Cat Diseases (drug therapy, pathology)
• Cats
• Drug Administration Schedule
• Fibrosarcoma (drug therapy, veterinary)
• Lomustine (administration & dosage, adverse effects, therapeutic use)
• Lymphoma (drug therapy, veterinary)
• Multiple Myeloma (drug therapy, veterinary)
• Neoplasms (drug therapy, veterinary)
• Neutropenia (chemically induced, veterinary)
• Retrospective Studies
• Thrombocytopenia (chemically induced, veterinary)
• Treatment Outcome